Lexicon Pharmaceuticals (LXRX) Earnings Analysis
Lexicon Pharmaceuticals (LXRX) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS -0.0026 USD vs -0.04 USD est (+93.5%). It has beaten estimates in 5/5 recent quarters (100%). Trailing P/E -31.51.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does LXRX next report earnings?
No confirmed upcoming earnings date is currently scheduled for LXRX. This page updates as the calendar is published.
LXRX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.0026 USD | -0.04 USD | +93.5% | Beat |
| 2026-03-05 | -0.04 USD | -0.07 USD | +42.9% | Beat |
| 2025-11-06 | -0.04 USD | -0.07 USD | +42.9% | Beat |
| 2025-03-06 | -0.09 USD | -0.11 USD | +18.2% | Beat |
| 2024-08-01 | -0.17 USD | -0.18 USD | +5.6% | Beat |
Beat rate: 5/5 (100%) over reported quarters with consensus data.
LXRX valuation and analyst view
| Trailing P/E | -31.51 |
|---|---|
| Trailing EPS | -0.06519 USD |
| Price / book | 4.44 |
| Dividend yield | 0.00% |
| Market cap | 0.98B |
| Analyst consensus | Hold (5 buy / 7 hold / 2 sell) |
| Avg price target | 6 USD |
Related research pages
Frequently asked questions
When is Lexicon Pharmaceuticals (LXRX)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for LXRX. This page updates as the calendar is published.
Did LXRX beat earnings last quarter?
In its 2026-05-07 report, LXRX posted EPS of -0.0026 USD versus a -0.04 USD estimate — a beat of 93.5%.
What is LXRX's earnings track record?
Over the last 5 reported quarters with consensus data, LXRX beat estimates 5 times (100%).
What is LXRX's current P/E ratio and EPS?
LXRX trades at a trailing P/E of -31.51 on trailing EPS of -0.06518588846691985 USD.
What do analysts rate LXRX?
Analyst consensus is "Hold" across 14 ratings (0 strong buy, 5 buy, 7 hold, 2 sell, 0 strong sell). Average 12-month price target: 6 USD.